Comparison of Nicotine Plasma Concentrations and Subjective Effects for Three Menthol Electronic Cigarettes vs Combustible Menthol Cigarettes and Nicotine Gum

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

71 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-31

Study Completion Date

2016-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to measure plasma nicotine uptake parameters, physiological measures, and subjective effect measures in smokers during and following a single ad libitum use of three menthol electronic cigarettes versus combustible menthol cigarettes and nicotine gum.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Nicotine Plasma Concentrations and Subjective Effects for Three Electronic Cigarettes vs Combustible Cigarettes and Nicotine Gum

NCT02269514

Smoking

COMPLETED NA

Use Behavior, Nicotine Uptake, and Subjective Effects Comparison of Tobacco and Menthol e-Liquids by ENDS Consumers

NCT05134415

Electronic Cigarette Use

COMPLETED NA

Nicotine Uptake, Measures of Abuse Liability, and Puffing Topography With Use of RELX ENDS Products by Smokers

NCT04640285

Electronic Cigarette Use

COMPLETED NA

Nicotine Pharmacokinetics and Subjective Effects of Oral Nicotine Products Relative to Smokeless Tobacco in Adult Users

NCT06691386

Tobacco Use

COMPLETED NA

Evaluation of Cessation Preferences of Menthol Smoker

NCT02020005

Smoking Cessation

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will assess various elements that may provide information regarding the potential for menthol electronic cigarettes (e-cigarettes) to be adopted by current smokers. These various elements include: a) nicotine pharmacokinetics (PK), b) physiological measures of pulse rate and blood pressure, and c) subjective effects measured by Urge to Smoke, Urge for Product, Product Rating, Intent to Use Product Again, and Product Effects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Smoking

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Own Brand Menthol Cigarette

Group Type ACTIVE_COMPARATOR

Own Brand Menthol Cigarette

Intervention Type OTHER

combustible menthol cigarette brand style smoked most frequently by subject

Electronic Menthol Cigarette #1

VUSE® (menthol flavor, 14 mg nicotine)

Group Type EXPERIMENTAL

Electronic Menthol Cigarette #1

Intervention Type OTHER

VUSE® Digital Vapor Cigarette (menthol flavor, 14 mg nicotine)

Electronic Menthol Cigarette #2

VUSE® (menthol flavor, 29 mg nicotine)

Group Type EXPERIMENTAL

Electronic Menthol Cigarette #2

Intervention Type OTHER

VUSE® Digital Vapor Cigarette (menthol flavor, 29 mg nicotine)

Electronic Menthol Cigarette #3

VUSE® (menthol flavor, 36 mg nicotine)

Group Type EXPERIMENTAL

Electronic Menthol Cigarette #3

Intervention Type OTHER

VUSE® Digital Vapor Cigarette (menthol flavor, 36 mg nicotine)

Leading U.S. Nicotine Gum

4 mg nicotine polacrilex gum

Group Type ACTIVE_COMPARATOR

Leading U.S. Nicotine Gum

Intervention Type OTHER

4 mg nicotine polacrilex gum

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Own Brand Menthol Cigarette

combustible menthol cigarette brand style smoked most frequently by subject

Intervention Type OTHER

Electronic Menthol Cigarette #1

VUSE® Digital Vapor Cigarette (menthol flavor, 14 mg nicotine)

Intervention Type OTHER

Electronic Menthol Cigarette #2

VUSE® Digital Vapor Cigarette (menthol flavor, 29 mg nicotine)

Intervention Type OTHER

Electronic Menthol Cigarette #3

VUSE® Digital Vapor Cigarette (menthol flavor, 36 mg nicotine)

Intervention Type OTHER

Leading U.S. Nicotine Gum

4 mg nicotine polacrilex gum

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Able to read, understand, and willing to sign an informed consent form and complete questionnaires written in English.
2. Generally healthy male or female, 21 to 60 years of age, inclusive, at Screening.
3. Expired breath carbon monoxide (ECO) level is ≥ 15 ppm and ≤ 100 ppm at the Screening and Randomization Visits, measured between 12 p.m. and 6 p.m.
4. Combustible menthol cigarettes are the only tobacco product used within (≤) 30 days of Screening.
5. Smokes combustible, filtered, menthol cigarettes, 83 mm to 100 mm in length.
6. Agrees to smoke usual brand (UB) menthol cigarette throughout the study period. Usual brand cigarette is defined as the menthol cigarette brand style currently smoked most frequently by the subject.
7. Smokes at least 10 menthol cigarettes per day (on average) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (prior to 30 days of Screening), or clinical study participation (prior to 30 days of Screening) will be allowed at the discretion of the Investigator.
8. Response at Screening to Fagerstrom Test for Nicotine Dependence, Question 1 ("How soon after you wake up do you smoke your first cigarette?") is either "Within 5 minutes" or "6 - 30 minutes."
9. Willing to use UB menthol cigarette, the study electronic cigarette menthol brand styles and nicotine gum during the study period.
10. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to check-in at each Test Visit.
11. Females of childbearing potential must be willing to use a form of contraception acceptable to the Investigator from the time of signing informed consent until study discharge.

Exclusion Criteria

1. Clinically significant or unstable/uncontrolled acute or chronic medical conditions at Screening, as determined by the Investigator, that would preclude a subject from participating safely in the study (e.g., uncontrolled hypertension, asthma or other lung disease, cardiac disease, neurological disease or psychiatric disorders) based on safety assessments such as clinical laboratory tests, medical history, and physical/oral examinations.
2. Systolic blood pressure of \> 150 mmHg or a diastolic blood pressure of \> 95 mmHg at Screening, measured after being seated for at least 5 minutes.
3. Hemoglobin level is \< 12 g/dL at Screening.
4. Positive test for Human Immunodeficiency Virus (HIV), Hepatitis B surface antigen, or Hepatitis C virus.
5. Postponing a decision to quit smoking (defined as planning a quit attempt within \[≤\] 30 days of Screening) to participate in this study or previous attempt within (≤) 30 days prior to Screening.
6. Employed by a tobacco company, the study site, or handles unprocessed tobacco as part of their job.
7. Use of any medication or supplement that aids smoking cessation, including but not limited to any nicotine replacement therapy (e.g., nicotine gum, lozenge, patch), varenicline (Chantix), bupropion (Wellbutrin, Zyban), or lobelia extract within (≤) 30 days of Screening.
8. Females ≥ 35 years of age currently using systemic, estrogen containing contraception or hormone replacement therapy.
9. A positive urine drug screen without disclosure of corresponding prescribed concomitant medication(s), at Screening or Randomization Visit. A positive alcohol result at Screening, Randomization Visit, or at any Test Visit.
10. A female who is pregnant, lactating, or intends to become pregnant during the course of the study.

Minimum Eligible Age

21 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes